COM701 shows antitumor activity in advanced solid tumors

COM701, a novel first-in-class immune checkpoint inhibitor, demonstrated antitumor activity alone and in combination with nivolumab among patients with advanced solid tumors, according to results of a phase 1 study presented at the virtual American Association for Cancer Research Annual Meeting.The agent also induced objective responses with and without nivolumab (Opdivo, Bristol-Myers Squibb) in difficult-to-treat tumor types, such as primary peritoneal and microsatellite stable colorectal cancer.“Remarkable advances in antitumor activity have been made during the past several years.Read More

Share on facebook
Share on twitter
Share on linkedin